Sterigenics International has announced that it has acquired Toxikon Europe, the European division of Toxikon Corporation.
Terms of the deal were not disclosed.
Toxikon Europe provides a suite of integrated analytical, material characterization and microbiological services to the pharmaceutical, medical device and biologics industries. The company’s unrivalled extractables and leachables (E&L) testing expertise and leading database enhance the flexibility and speed with which its life science customers can bring their products to market.
This acquisition provides a more comprehensive service offering and a platform for growth for Sterigenics International’s Nelson Labs business. Nelson Labs will now offer Toxikon Europe’s leading E&L capabilities to its customers around the world and in kind, offer Nelson Labs leading microbiological services to Toxikon Europe’s customers.
CEO of Sterigenics International Michael B Petras Jr said: “Toxikon Europe’s geographic foothold and expert analytical testing platform enable our global expansion and ability to provide significantly greater value to customers.
“We are excited to welcome a strong management team, with over 150 years of industry experience, and the highly trained Toxikon Europe employees to our company.”
Toxikon Europe’s capabilities are both complementary and additive to Nelson Labs’ existing testing portfolio and, in combination, make Nelson Labs one of the premier global E&L laboratory testing platforms for the pharmaceutical and medical device industries.
As part of this deal, Nelson Labs and Toxikon USA will enter a long-term supply arrangement under which Nelson Labs will outsource their in-vivo biocompatibility to Toxikon USA.
President of Nelson Labs Jeff Nelson said: “The acquisition of Toxikon Europe and our ongoing partnership with Toxikon USA support our strategy to offer greater breadth of services to meet the demands of our rapidly growing, global customers.
“We are now able to serve the pharmaceutical and medical device industries continuously from the early stages of product development through manufacturing, sterilization, and testing.”
“For Toxikon Europe, the acquisition by Sterigenics International validates our success and provides our customers with additional resources,” said Dr. Laxman Desai, President and CEO, Toxikon Corporation. “Our team at Toxikon USA looks forward to our continued partnership with Nelson Labs.”
Managing director of Toxikon Europe Jos Bollen added: “Our customers, who are increasingly concerned about quality and safety, will continue to receive the superior service and quality they have come to know from Toxikon Europe. In addition, our breadth of service and our reach will be enhanced with the expertise and industry leadership of Sterigenics International’s Nelson Labs.”
About Toxikon Europe.
Toxikon Europe is an independent, privately owned contract research organization (CRO), specialized in providing premium E&L services to the pharmaceutical industry. Based in Belgium, Toxikon Europe supports pharmaceutical companies worldwide to develop international compliance, including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) testing strategies.
The company qualifies containers / closure applications and pharmaceutical production equipment from an E&L perspective. In addition, the Toxikon group provides biocompatibility testing services (in-vivo and in-vitro testing) to both the medical device and pharmaceutical Industries.
Toxikon is ISO 17025 accredited, good laboratory practice (GLP) certified and good manufacturing practice (GMP) accredited. Toxikon is also FDA registered.